Global Japanese Encephalitis Vaccines Market Size By Type (Attenuated Vaccines, Inactivated Vaccines), By Application (Adults, Children), By Region, And Segment Forecasts, 2023 to 2032

The Global Japanese Encephalitis (JE) Vaccines Market was valued at USD 0.29 billion in 2023 and is projected to surpass USD 0.47 billion by 2031, growing at a CAGR of 6.2% during the forecast period of 2023-2031. This market is primarily driven by the increasing incidence of Japanese encephalitis in endemic regions, growing awareness about vaccine-preventable diseases, and expanded government immunization initiatives. Japanese encephalitis, a mosquito-borne viral infection, continues to pose significant health risks, particularly in Asia-Pacific regions, leading to sustained demand for effective vaccination programs.

Drivers:

Rising Incidence in Endemic Regions:

Countries in Asia-Pacific, particularly India, China, Nepal, and Vietnam, report recurring JE outbreaks. The World Health Organization (WHO) has classified JE as a major public health concern in these areas, which has prompted increased investment in vaccination initiatives.

Expanded Immunization Programs:

Global and national immunization campaigns, including those sponsored by organizations such as GAVI and WHO, are improving vaccine coverage rates. Public-private partnerships are accelerating the availability of JE vaccines in low- and middle-income countries.

Growing Awareness and Diagnostic Improvements:

Increased access to diagnostics and public health education has improved case detection and surveillance, boosting vaccine demand in both endemic and non-endemic regions with potential travel-related exposure.

Restraints:

Cold Chain and Distribution Challenges:

JE vaccines often require cold chain logistics, posing hurdles in rural or underdeveloped regions. These logistical issues can limit effective vaccine delivery and coverage.

Low Awareness in Non-Endemic Regions:

Outside of endemic areas, public and healthcare provider awareness of JE remains limited, reducing demand for travel-related vaccinations despite rising international tourism to Asia-Pacific countries.

Opportunity:

Introduction of Combination Vaccines and Single-Dose Regimens:

The market is seeing a surge in R&D focused on simplifying JE vaccine schedules, including combination vaccines and single-dose options, which can increase compliance and broaden coverage.

Penetration into New Markets:

Untapped regions within Africa and Southeast Asia, along with increasing international travel, present opportunities for broader market expansion beyond traditional endemic zones.

Market by System Type Insights:

Based on system type, the Inactivated JE Vaccines segment held the largest market share in 2023. These vaccines are well-established, offer a favorable safety profile, and are widely used in national immunization programs. However, the Live Attenuated Vaccines segment is anticipated to witness the fastest growth due to its cost-effectiveness and long-lasting immunity with fewer doses, making it ideal for mass campaigns.

Market by End-use Insights:

The Public Health Programs segment dominated the market in 2023, accounting for over 65% of global revenue. This includes government-led vaccination initiatives, largely in endemic countries. The Private Clinics and Travel Health Services segment is expected to grow steadily as travel-related vaccination gains prominence among tourists and expatriates heading to endemic regions.

Market by Regional Insights:

Asia-Pacific remains the largest and most dominant market for JE vaccines, with countries like China, India, and Japan leading in both production and consumption. The presence of a high-risk population and robust immunization infrastructure supports this dominance. North America and Europe are emerging growth markets, driven primarily by rising travel-related vaccination needs and growing awareness of JE risks among travelers.

Competitive Scenario:

Major players in the Global Japanese Encephalitis Vaccines Market include Sanofi Pasteur, Chengdu Institute of Biological Products, Biological E Limited, Valneva SE, Bharat Biotech, and Kaketsuken. These companies are focusing on expanding vaccine production, entering public procurement contracts, and innovating in terms of dosage schedules and thermostability. For example:

In 2023, Valneva SE received extended WHO prequalification for its live attenuated JE vaccine, allowing broader global distribution.

Bharat Biotech expanded its distribution reach to Latin America and parts of Africa through new public-private partnerships in 2024.

Scope of Work – Global Japanese Encephalitis Vaccines Market

Key Market Developments:

May 2023 – Sanofi Pasteur collaborated with the Indian government to deliver JE vaccines through national immunization days, expanding coverage to over 10 million children.

September 2024 – Bharat Biotech initiated clinical trials for a thermostable single-dose JE vaccine targeting use in rural and remote regions.

January 2025 – Valneva SE announced the expansion of JE vaccine production capacity to meet increased demand from Southeast Asia.

FAQs:

1) What is the current market size of the Global Japanese Encephalitis Vaccines Market?

The market was valued at USD 0.29 billion in 2023.

2) What is the major growth driver of the Global Japanese Encephalitis Vaccines Market?

Rising incidence in endemic regions and expanded immunization programs are the major growth drivers.

3) Which is the largest region during the forecast period in the Global Japanese Encephalitis Vaccines Market?

Asia-Pacific is the largest and most dominant region due to its high disease burden and widespread vaccination efforts.

4) Which segment accounted for the largest market share in the Global Japanese Encephalitis Vaccines Market?

The Inactivated JE Vaccines segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Japanese Encephalitis Vaccines Market?

Key players include Sanofi Pasteur, Valneva SE, Bharat Biotech, Chengdu Institute of Biological Products, and Biological E Limited.